Epizyme, Inc. to Present at Upcoming Events in June

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced its participation in two upcoming events in June:

• 13th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Saturday, June 20. At ICML, updated data from the ongoing Phase 1 trial of EZH2 inhibitor tazemetostat (EPZ-6438) in advanced B-cell non-Hodgkin lymphoma (NHL) or advanced solid tumors will be presented at 10:35 a.m. CEST / 4:35 a.m. ET. Concurrent with the release of the data, the Company plans to post the presentation on its website at www.epizyme.com.Epizyme will host a conference call and live audio webcast on Monday, June 22 at 8:00 a.m. ET to review the tazemetostat data presented at ICML. To participate in the conference call, please dial 1-877-844-6886 (domestic) or 1-970-315-0315 (international) and refer to conference ID 64265218.

• JMP Securities Life Sciences Conference 2015 at the St. Regis Hotel in New York on Wednesday, June 24 at 11:30 a.m. ET.

Live webcasts and archived replays for the June 22 ICML Recap and the June 24 JMP Securities presentations will be available by visiting the Investor Center of the Epizyme website at www.epizyme.com.

About EZH2 Cancers

EZH2 is a histone methyltransferase (HMT) that is increasingly understood to play an important oncogenic role in a number of cancers. These include non-Hodgkin lymphomas, INI1-deficient cancers such as malignant rhabdoid tumors, epithelioid sarcomas, synovial sarcoma, and a range of other solid tumors.

About Tazemetostat (EPZ-6438)

Epizyme is developing tazemetostat for the treatment of non-Hodgkin lymphoma patients and patients with INI1-deficient solid tumors. Tazemetostat is a first-in-class small molecule inhibitor of EZH2 created by Epizyme using its proprietary product platform. In many human cancers, mis-regulated EZH2 enzyme activity results in misregulation of genes that control cell proliferation resulting in the rapid and unconstrained growth of tumor cells. Tazemetostat is the WHO International Non-Proprietary Name (INN) for compound EPZ-6438.

Tazemetostat is the first EZH2 inhibitor to enter human clinical development.

Additional information about this program, including clinical trial information, may be found here: https://clinicaltrials.gov/ct2/show/NCT01897571

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150615005699/en/

Media/Investors:
Epizyme, Inc.
Andrew Singer, 617-500-0712
Executive Vice President and Chief Financial Officer
[email protected]

Source: Epizyme, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
• Inter Pag Selects ACI Worldwide to Advance Intelligent Payments Orchestration in Brazil
• NBPE Announces Transaction in Own Shares